BG Medicine, Inc. (BGMD)

Market Cap	11.00
Revenue (ttm)	1.57M
Net Income (ttm)	-6.96M
Shares Out	11.37M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	461
Open	n/a
Previous Close	0.0001
Day's Range	n/a
52-Week Range	n/a
Beta	81.95
RSI	24.76
Earnings Date	n/a

About Instructure Holdings

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and is...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: BGMD

Financial Performance

In 2015, BG Medicine's revenue was $1.57 million, a decrease of -43.81% compared to the previous year's $2.79 million. Losses were -$6.96 million, -13.72% less than in 2014.